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ABSTRACT
Extracellular calcium participates in several key physiological
functions, such as control of blood coagulation, bone calciﬁca-
tion or muscle contraction. Calcium homeostasis in humans is
regulated in part by genetic factors, as illustrated by rare
monogenic diseases characterized by hypo or hypercalcaemia.
Both serum calcium and urinary calcium excretion are herit-
able continuous traits in humans. Serum calcium levels are
tightly regulated by two main hormonal systems, i.e. parathy-
roid hormone and vitamin D, which are themselves also inﬂu-
enced by genetic factors. Recent technological advances in
molecular biology allow for the screening of the human gen-
ome at an unprecedented level of detail and using hypothesis-
free approaches, such as genome-wide association studies
(GWAS). GWAS identiﬁed novel loci for calcium-related phe-
notypes (i.e. serum calcium and 25-OH vitamin D) that shed
new light on the biology of calcium in humans. The substantial
overlap (i.e. CYP24A1, CASR, GATA3; CYP2R1) between
genes involved in rare monogenic diseases and genes located
within loci identiﬁed in GWAS suggests a genetic and pheno-
typic continuum between monogenic diseases of calcium
homeostasis and slight disturbances of calcium homeostasis in
the general population. Future studies using whole-exome and
whole-genome sequencing will further advance our under-
standing of the genetic architecture of calcium homeostasis
in humans. These ﬁndings will likely provide new insight
into the complex mechanisms involved in calcium homeo-
stasis and hopefully lead to novel preventive and therapeutic
approaches.
Keyword: calcium, monogenic, genome-wide association
studies, genetics
INTRODUCTION: CONTROL OF CALCIUM
HOMEOSTASIS
Extracellular calcium participates in several key physiological
functions, such as control of blood coagulation, bone calciﬁca-
tion or muscle contraction. Even if important calcium ﬂuxes are
exchanged between organs implicated in the import, storage
and export in and out of the organism (the intestine, bone and
kidneys), serum calcium concentration is kept stable, with varia-
tions that do not exceed 2–3% and that are mainly due to circa-
dian rhythmicity [1]. However, even with a thorough control of
its concentration, calcium reaches saturation levels in the
plasma and only strong inhibitors, e.g. magnesium, fetuin A or
albumin, can prevent precipitation and stabilize calciprotein
particles [2]. Although calcium has crucial physiological roles,
it can do harm if deposited inappropriately.
Regulation of extracellular calcium concentration and bio-
mineralization depends upon a complex network of hormones
and intricate feedback loops. Like sodium homeostasis,
which is regulated by both, a short-term-acting and G-protein-
coupled receptor (GPCR)-dependent system (angiotensin 2)
and a long-term-acting and nuclear receptor-dependent
hormone (aldosterone), calcium homeostasis is maintained
mainly by two systems, the parathyroid hormone (PTH) and
vitamin D.
PTH
Biologically active PTH is a peptide that interacts, with high
afﬁnity, with PTH receptor 1 (PTHR1), triggering downstream
intracellular signalling. PTH is synthetized as a pre-prohormone
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in the parathyroid glands and is secreted in a pulsatile man-
ner, with infradian and circadian rhythms, in the blood stream
as a 1–84 fragment (intact PTH). The half-life of biologically
active PTH in the circulation is only a few minutes before it is
degraded in a variety of smaller processed fragments with
largely unknown functions [3, 4]. Recent data indicate that oxi-
dation of PTH in certain clinical circumstances such as renal in-
sufﬁciency could decrease the afﬁnity of PTH for its receptor
[5]. Parathyroid glands exert two major functions regarding
calcium: sensing plasma calcium concentration—free-ionized
calcium only—and adapting secretion of PTH. Once released in
the bloodstream, PTH augments serum calcium levels directly
by increasing calcium reabsorption by the kidney, calcium
release by the bone and indirectly by increasing intestinal
calcium uptake.
CALCIUM-SENSING RECEPTOR
In contrast to other ions for which it has been postulated that
sensors exist but were never discovered, the identiﬁcation of
the calcium-sensing receptor (CASR) by Brown and Hebert
was instrumental in deciphering a main passive regulator of
serum calcium concentration [6]. First, by its expression in the
parathyroid gland, CASR directly connects calcium sensing
and control of PTH secretion and its downstream conse-
quences. However, the effects of the CASR on calcium homeo-
stasis extend beyond the parathyroid glands. Expressed in the
intestine and the bone, CASR may regulate calcium ﬂuxes in
these organs even though its precise role is not fully estab-
lished [7, 8]. In contrast, in the kidney, CASR has been shown
to control serum calcium concentration independently of its
effect on PTH secretion. Indeed, using double CASR–PTH
knockout mice, Kantham et al. [9] showed that CASR defends
against hypercalcaemia independently from PTH. Toka et al.
[10] did provide additional evidence consistent with these
results by studying CASR kidney-speciﬁc knockout mice.
Finally, an elegant study by Loupy et al. [11] showed that
CASR in the thick ascending limb regulates serum calcium
concentration independently of PTH. Altogether, these studies
displayed strong evidence that regulation of renal calcium ex-
cretion by CASR directly inﬂuences calcium homeostasis and
identiﬁed CASR as a primary regulator of serum calcium con-
centration, independently of its effect on PTH secretion.
VITAMIN D
To ﬁt with the high afﬁnity in the ligand pocket of the nuclear
receptor vitamin D receptor (VDR) and produce its effects,
vitamin D needs to be activated by two hydroxylation steps, at
position 25 and 1. It is not yet fully elucidated, which enzyme
hydroxylates vitamin D at position 25 in the liver. One candi-
date is the mitochondrial cytochrome P450, subfamily 27,
polypeptide 1 (CYP27A1), which is, however, mainly involved
in cholesterol and bile acid metabolism and has high-capacity
but only low-afﬁnity 25-hydroxylase activity [12]. Since mice
and humans with a CYP27A1mutation exhibit normal 25-OH
vitamin D concentrations, this enzyme probably plays a minor
role in the transformation of vitamin D [13]. Another pro-
posed enzyme involved in the 25-hydroxylation of vitamin D
in the liver is the low-capacity, high-afﬁnity microsomal cyto-
chrome P450, subfamily 2R, polypeptide 1 (CYP2R1) [14].
CYP2R1 plays a crucial role in the metabolism of vitamin D,
since patients and mice with homozygous mutations in this
gene display low-circulating 25-OHD levels and rickets [15].
Surprisingly, double knockout mice for CYP2R1 and CYP27A1
exhibit normal levels of serum 25(OH) vitamin D, and no
rickets, suggesting that another 25-hydroxylase exists and
needs to be identiﬁed, at least in the mouse [16]. The second
and highly regulated hydroxylation is much better character-
ized. CYP27B1 (1-alpha hydroxylase) is a highly regulated
enzyme from the CYP450 family. Calcium, phosphate, PTH,
calcitonin and the ﬁbroblast growth factor 23 (FGF23)-Klotho
axis are the main regulatory factors of CYP27B1, whereas
1,25(OH)2 vitamin D inhibits, in a negative feedback loop
on CYP27B1, its own production. Vitamin D homeostasis
depends, however, not only on production, but also on degrad-
ation, which is also highly regulated. Cytochrome P450, family
24, subfamily A, polypeptide 1 (CYP24A1), hydroxylates 1,25
(OH)2 vitamin D and targets it for further catabolism into
calcitroic acid and excretion. CYP24A1 is regulated, at the
transcriptional level, in an antagonistic manner compared
with CYP27B1, by calcium, phosphate, PTH, FGF23, Klotho
and is activated by high levels of circulating 1,25(OH)2
vitamin D, thus inducing its own degradation. Active 1,25
(OH)2 vitamin D stimulates intestinal calcium absorption, in-
creases bone mineralization, but also bone resorption and
favours calcium reabsorption by the kidney.
The main mechanisms of calcium homeostasis described
here have been further explored at the molecular level by ge-
neticists. This review now emphasizes how studies on rare
monogenic diseases in patients bearing disturbances of calcium
homeostasis allowed precise dissection of the molecular path-
ways involved in these pathologies. Moreover, we will show
that hypothesis-free genome-wide association studies (GWAS)
conducted in large population-based samples are powerful in
detecting new genetic determinants of serum calcium and in
validating known actors involved in the control of serum
calcium levels. This review does not cover non-genetic causes
of hyper or hypocalcaemia.
GENETICS OF CALCIUM HOMEOSTASIS
Familial aggregation and heritability
Both serum calcium and urinary calcium excretion have
been shown to be heritable continuous traits in humans [17].
In 1747 pairs from the UK Adult Twin Registry, heritability
was estimated to be 33% (95% CI: 21–45%) for serum calcium
and 52% (95% CI: 41–61%) for 24-h urinary calcium excretion
[17]. The unimodal distributions of serum calcium (symmetric
and close to normal) and 24-h urinary calcium excretion
(positively skewed, close to log-normal) in the general
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population suggest that numerous genetic factors (i.e. polygen-
ic traits) play a role in their control. The existence of rare
monogenic diseases with disturbances in calcium homeostasis
further underscores the importance of genetic factors. Similar
to other phenotypes, it is likely that a genetic and phenotypic
continuum exists between rare monogenic disorders of
calcium homeostasis and genetic factors responsible for the
control of calcium homeostasis in the general population
(Figure 1). This continuum can be described as follows: (i)
several mutations in a single gene can lead to the same mono-
genic disease (e.g. VDR, CASR [18]); (ii) different mutations in
a single gene may lead to several monogenic disorders (e.g.
CASR); (iii) although the genetic effect size within a monogen-
ic context is usually large, other genes may modify the pene-
trance of the main mutation (e.g. CASR–PTH [19]); (iv) genes
involved in rare monogenic diseases may play a role in com-
mon complex diseases and phenotypes (e.g. CASR, CYP24A1);
(iv) a polygenic disorder/phenotype is considered to result
from the addition of many small genetic effects, although one
cannot exclude a mixture of big and small effects.
Genome-wide association studies
GWAS have made an important contribution to our under-
standing of the genetic determinants of human traits [20].
GWAS allow a hypothesis-free exploration of the entire
human genome and identify genomic regions robustly asso-
ciated with phenotypes of interest. Current DNA chips usually
include 500 000 to 1 million single nucleotide polymorphisms
(SNPs) to be genotyped at an affordable cost. During the past
decade >2000, robust associations have been published in
GWAS [20].
What are the principles underlying GWAS?
Once participants have been genotyped, several steps are
conducted until a clean data set is obtained. In a second stage,
additional genetic variants are being inferred using the linkage
disequilibrium structure (so-called ‘haplotype blocks’) of the
human genome and publicly available HapMap and/or 1000
Genomes data (so-called ‘imputed SNPs’). First generation
GWAS focused on common alleles (i.e. with a minor allele fre-
quency usually >5%). More recent DNA chips now also allow
the measuring of rarer genetic variants. The fact that GWAS
focused on common variants does not imply that some of the
association signals from GWAS do not arise from multiple
rare variants. This results from the fact that a GWAS signal is
not restricted to the so-called top SNP (i.e. SNPs with the
lowest association P-value in a given region), but also includes
the entire region. The length of the captured region strongly
depends on the local linkage disequilibrium structure (i.e. cor-
relation structure).
Once a speciﬁc region of the genome has been identiﬁed as
being robustly associated with a phenotype of interest, a much
additional work is needed to unravel the causal variant(s).
Whenever a single gene is included in the associated region,
this task is much easier than when dozens of genes are
present. Also, the SNPs most signiﬁcantly associated with the
phenotype of interest are unlikely to be the true underlying
causal variant.
When compared with candidate gene studies published
before the GWAS era, GWAS ﬁndings are more robust in that
they have to be replicated before the results can be published.
As most GWAS associations correspond to small effect sizes,
very large sample sizes are usually needed to replicate ﬁndings.
GWAS are, therefore, less likely to generate false-positive
ﬁndings than earlier candidate gene studies that were often
underpowered and hard to replicate. Of note, the size of the
effect from a GWAS signal provides limited information on
the importance of the corresponding gene in the phenotype
under study. SNPs available in genome-wide DNA arrays only
represent a small subset of all SNPs throughout the human
F IGURE 1 : Genes involved in regulation of serum calcium concentration. Genes have been identiﬁed either by studies of monogenic diseases
or by GWAS performed on serum calcium and on vitamin D. Genes represented in green are mainly involved in the PTH axis and those in red
are mainly involved in the vitamin D axis. No GWAS has been conducted on PTH levels so far.
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genome and genomic regions (and genes) are not equally well
covered on these chips. A logical consequence of the need to
replicate ﬁndings across studies (and hence across settings) is
that GWAS results are typically robust to environmental con-
ditions. The presence of a strong gene-by-environment inter-
action may therefore not be captured in GWAS, unless this
speciﬁc interaction is adequately explored.
GWAS for calcium-related phenotypes
So far, only a few GWAS have focused on phenotypes
related to calcium [21–23]. For serum total calcium, the largest
study published so far comes from the CalciGen consortium
and identiﬁed six genomic regions as being robustly associated
with serum calcium in 39 400 individuals of European descent
from 17 population-based cohorts. This study explored the
genetic regions associated with total serum calcium in the
general population under free living conditions. The six repli-
cated SNPs for serum calcium were (i) rs1570669 near CYP24A1,
(ii) rs10491003 upstream of GATA3 (GATA-binding pro-
tein 3), (iii) rs7481584 in CARS (cysteinyl-tRNA synthetase),
(iv) rs1550532 in DGKD (diacylglycerol kinases delta), (v)
rs7336933 near DGKH (diacylglycerol kinases eta)/KIAA0564
and (vi) rs780094 in GCKR [glucokinase (hexokinase 4) regu-
lator] [23]. This study also conﬁrmed the strong association of
rs1801725 in the CASR locus with serum calcium that had
been previously identiﬁed in two separate GWAS [21, 22]. The
ﬁrst three signals implicate regions involved in Mendelian dis-
orders of calcium homeostasis. Two loci located on different
chromosomes are near genes that encode two different diacyl-
glycerol kinases, namely DGKH and DKGD. Although further
studies are needed to conﬁrm that these two genes are indeed
responsible in these signals, this result suggests a role of diacyl-
glycerol kinases in calcium homeostasis in humans.
Altogether, loci identiﬁed by the CalciGen consortium only
explain a tiny fraction of the variance of serum calcium levels
[23]. The top hit for serum calcium (rs1801725, a missense
CASR variant), by far the largest effect of all genome-wide sig-
niﬁcant signals for serum calcium, only explains 1.26% of
serum calcium variance [22], despite the fact the CASR plays a
major role in calcium homeostasis. This sharply contrasts with
the high heritability of serum calcium levels. The reasons for
this ‘missing heritability’, which is shared by most complex
phenotypes, are a hotly debated issue in the current literature
[24]. It is likely that a larger GWAS meta-analysis would iden-
tify additional serum calcium loci. It may appear as a surprise
that genes such as TRPV5 (transient receptor potential cation
channel, subfamily V, member 5), TRPV6 (transient receptor
potential cation channel, subfamily V, member 6), ATP2B1
(ATPase, Ca++ transporting, plasma membrane 1), PTH,
PTHR, VDR, Klotho and SLC8A1 [solute carrier family 8
(sodium/calcium exchanger), member 1], known to play a key
role in calcium transport in the intestine, bone and/or kidney
or in calcium homeostasis, did not come up in the CalciGen
GWAS meta-analysis. Such an absence of association does not
at all imply that these genes are not important for calcium
homeostasis in humans. We are not aware that any GWAS for
urinary calcium excretion or fractional excretion of calcium
have been published so far.
The ﬁrst published GWAS for 25(OH)D was conducted in
4501 individuals of European descent and identiﬁed the
rs2282679 near GC [group-speciﬁc component (vitamin D-
binding protein], rs3829251 near NADSYN1 (NAD synthetase
1)/DHCR7 (7-dehydrocholesterol reductase) and rs2060793
near CYP2R1 variants as being signiﬁcantly associated with
25(OH)D levels [25]. In a later GWAS meta-analysis, three loci
achieved genome-wide signiﬁcance and replication for 25
(OH) vitamin D levels in 30 000 participants of European
descent: (i) rs2282679 in GC; (ii) rs12785878 near NADSYN1/
DHCR7 and (ii) rs10741657 near CYP2R1, whereas the
CYP24A1 rs6013897 variant had genome-wide signiﬁcance in
the pooled sample [26]. These loci collectively explained be-
tween 1 and 4% of 25(OH) variance. GC is involved in vitamin
D transport; DHCR7 is involved in the synthesis, and CYP2R1
in the hydroxylation, of cholesterol. Identiﬁcation of CYP2R1
by GWAS for 25(OH)D strengthens its implication as the
main 25-hydroxylase for vitamin D. A GWAS conducted in
572 Caucasian children with asthma did not identify addition-
al variants associated with 25(OH)D [27]. So far variants iden-
tiﬁed in GWAS only explain a small proportion (∼5%) of the
heritability of 25(OH)D estimated by twin- and family studies
[28]. Additional studies are needed to further decipher genetic
determinants of 25(OH) vitamin D levels in humans.
A single GWAS, in 229 Hispanic Americans, was con-
ducted for 1,25(OH)2D and no genome-wide signiﬁcant
signal was identiﬁed, yet 8 SNPs from a set of 50 selected SNPs
were replicated for 1,25(OH(2)D in a larger cohort: rs6680429,
rs1348864, rs4559029, rs12667374, rs7781309, rs10505337,
rs2486443 and rs2154175 [29]. Larger sample sizes are clearly
needed to achieve sufﬁcient power to detect and replicate
signals across studies.
Rare monogenic diseases involved in serum
calcium control
Genetic determinants of serum calcium levels are numer-
ous and can be grouped into those affecting the CASR, PTH,
vitamin D and other calcium regulatory axis. Since the pioneer
work of Fuller Albright in the 1930s, large collections of rare
conditions in which plasma calcium is disturbed either towards
higher or lower levels have been identiﬁed, described, explored
and categorized. With the emergence of molecular medi-
cine, old unique entities have been subcategorized in a vari-
ety of conditions that can now be better explained and treated,
e.g. familial hypocalciuric hypercalcaemia (FHH), previously
thought to be a single condition which is now genetically
heterogeneous, with at least three causative genes identiﬁed
[CASR, GNA11 (guanine nucleotide-binding protein (G pro-
tein), alpha 11), AP2S1 (adaptor-related protein complex 2,
sigma 1 subunit)]. If precise and complete clinical descriptions
of patients are still mandatory, new powerful molecular tools
have facilitated and accelerated the diagnosis and the discovery
of genes causing orphan diseases. Some of the main rare dis-
eases affecting calcium plasma levels are discussed hereafter
(Table 1). Owing to space constraints, only a selection of con-
ditions and publications is highlighted here and this review is
neither systematic nor exhaustive.
N
D
T
P
E
R
S
P
E
C
T
IV
E
S
iv58 O. Bonny and M. Bochud
 at U
niversitÃ© & EPFL Lausanne on September 29, 2014
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
CONDITIONS AFFECTING THE PTH AXIS
PTH being produced mainly by the parathyroid glands in
humans, every inherited condition affecting the presence of
the glands will be translated into major calcium dysregulation.
Indeed, hypoplasia or aplasia of the parathyroid glands, such
as seen in Di George syndrome (due to hemizygous deletion
of ∼1.5–3 Mb on the 22q11.2 locus and affecting in particular
TBX1 [30]) or in familial isolated hypoparathyroidism (due
to mutations in the genes coding for GCM2 (glial cells
missing, Drosophila, homologue 2) [31]) results in severe
hypoparathyroidism and hypocalcaemia. A similar pheno-
type, with yet preserved glands, can be seen in patients
carrying loss of function mutations in the PTH-coding gene.
The reader is encouraged to consult the excellent review of
Gregorieva and Thakker for further information on these
conditions [32]. New entities for hypoparathyroidism have
been elucidated. FAM111A (family with sequence similarity
111, member A) is a gene of unknown function recently
identiﬁed as causative for Kenny–Caffey syndrome and for
osteocraniostenosis, including hypocalcaemia, primary hypo-
parathyroidism and bone anomalies [33]. Its role in PTH and
bone metabolism is still unclear. GATA3 is a transcription
factor involved in the development of the kidney (ureteric
bud), and parathyroid gland. Mutations in GATA3 lead to
hypoparathyroidism, deafness and renal dysplasia, an auto-
somal-dominant trait in which hypocalcaemia and very low
levels of PTH are associated with renal dysplasia and sensori-
neural deafness [34].
In contrast, MENIN is a tumour suppressor protein in-
volved in chromatin remodelling and expressed in several
glandular tissues. When mutated, the coding gene MEN1
(multiple endocrine neoplasia syndrome type 1) leads to hypo-
morphic MENIN production that results in a complex MEN1.
Primary hyperparathyroidism is one of the most frequently
encountered complications of the syndrome, leading to classic
hypercalcaemia/hypophosphataemia with inappropriately high
PTH levels.
PTH mediates its effect via PTHR1 which is a GPCR. Mu-
tations in the genes coding for PTHR1 and for G protein
alpha S (encoded by GNAS) that transduces the signal intracel-
lularly, leads to peripheral resistance to PTH effects. This
entity is called pseudo-hypoparathyroidism and leads to severe
bone anomalies (chondrodysplasia of several types, including
Eiken syndrome [35]) and renal resistance to PTH action. As
GNAS is highly methylated, the phenotype depends on the
parental inheritance of the mutated gene. A detailed descrip-
tion of the different subtypes of pseudo-hypoparathyroidism
is beyond the scope of this review but can be found in Levine
et al. [36].
CASR-ASSOCIATED DISEASES
Human loss-of-function mutation in the CASR gene causes
FHH when one allele is mutated and neonatal severe hyper-
parathyroidism (NSHPT) when both alleles are affected. FHH
is characterized by decreased urinary calcium excretion and
Table 1. Monogenic diseases leading to serum calcium disturbances
Target Gene Mechanism Disease OMIM Effect on plasma
calcium
CASR CASR Loss of function,
Heterozygous
FHH type 1 145980 Hypercalcaemia
Loss of function,
Homozygous
NSHPT 239200 Hypercalcaemia
Activating mutation ADH type 1, including Bartter-like syndrome 601198 Hypocalcaemia
GNA11 Loss of function FHH type 2 145981 Hypercalcaemia
Activating mutation ADH type 2 615361 Hypocalcaemia
AP2S1 Loss of function FHH type 3 600740 Hypercalcaemia
Parathyroid
gland – PTH axis
MEN1 Loss of Function MEN type 1 with hyperparathyroidism 131100 Hypercalcaemia
PTH Loss of function Familial isolated hypoparathyroidism 146200 Hypocalcaemia
GCM2 Loss of function Familial isolated hypoparathyroidism 146200 Hypocalcaemia
TBX1 and
others (?)
Deletion chromosome
22
Di George, velocardiofacial, Catch22 syndrome 188400 Hypocalcaemia
FAM111A Loss of function Hypoparathyroidism and bone dysplasia 615292 Hypocalcaemia
GATA3 Loss of function Hypoparathyroidism, renal dysplasia,
sensorineural deafness
146255 Hypocalcaemia
GNAS Loss of function Pseudo-hypoparathyroidism 103580 Hypocalcaemia
PTHR1 Chondrodysplasia
- Murk Jansen
- Blomstrand
- Eiken
156400
215045
600002
Hypercalcaemia
Vitamin D CYP27B1 Loss of function Vitamin D-dependent rickets 1A 264700 Hypocalcaemia
CYP2R1 Loss of function Vitamin D-dependent rickets 1B 600081 Hypocalcaemia
VDR Loss of function Vitamin D-dependent rickets 2A 277440 Hypocalcaemia
HNRNPC Loss of function Vitamin D-dependent rickets 2B 164020 Hypocalcaemia
CYP24A1 Loss of function Infantile hypercalcaemia 143880 Hypercalcaemia
Secondary causes were omitted (e.g. hypomagnesaemia with secondary hypocalcaemia, hypophosphataemia…).
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PTH-dependent hypercalcaemia, while NSHPT leads to severe
early hyperparathyroidism and hypercalcaemia [37]. In mice in
which CASR has been deleted, the severe phenotype mimicking
human NSHPT could be rescued by suppressing PTH, as ele-
gantly showed in experiments during which PTH and CASR
were simultaneously inactivated [38]. The fact that these mice
harbour only slightly elevated, but highly variable plasma calcium
suggests that the regulation of serum calcium concentration and
PTH by the CASR occurs independently. The hypocalciuria ob-
served in CASR KO mice was not rescued in the double CASR–
PTH knockout animals, suggesting that CASR in the kidney is
necessary for normal calcium excretion by preventing excessive
calcium reabsorption independently of PTH [39]. In contrast,
gain-of-functionmutations in theCASR gene observed inhumans
lead to autosomal-dominant hypocalcaemia type 1 (ADH1)
[40]. Similarly, mice carrying an activating mutation in CASR
exhibit hypocalcaemia, hypoparathyroidism, and hyperphospha-
taemia and decreased renal calcium reabsorption [41].
Further sequencing of CASR-negative FHH patients pro-
vided new insights into our understanding of the regulatory
pathways of the CASR and identiﬁed genetic heterogeneity in
this syndrome. FHH type 1 is the classical form due to CASR
mutations. FHH type 2 is phenotypically similar, but results
from loss-of-function mutations in a gene coding for the
protein G alpha 11 (GNA11) [42]. This indicates that this
protein G is implicated in the downstream intracellular signal-
ling of CASR. Interestingly, activating mutations in the same
gene could lead to the mirror image, i.e. ADH type 2, as seen
with CASR. Finally, FHH type 3 patients, who have a different
and more severe clinical course, including increased serum
PTH concentrations, hypophosphataemia and osteomalacia
were found to carry mutations in the gene coding for adaptor
protein 2 sigma subunit (AP2S1), a protein involved in cla-
thrin-mediated endocytosis [43]. This suggests that regulation
of CASR endocytosis is critical for its normal function. This
ﬁnding perfectly illustrates the fact that studying rare mono-
genic diseases may uncover new pathogenic mechanisms and
in this case, identify new regulatory pathways for CASR and
calcium homeostasis.
CONDITIONS AFFECTING THE VITAMIN D
AXIS
In family-based studies, heritability estimates ranged from 20 to
80% for circulating levels of vitamin 25-OH-D(3) and from 30
to 48% for 1,25-OH(2)-D(3) levels [44, 45], which justiﬁes the
search for genetic determinants. In a twin study in Vietnam,
heritability of 25(OH) vitamin D was high and signiﬁcant in
winter (70%), but not in summer, which suggests a predomin-
ant role of environmental conditions in summer [46].
Active 1,25(OH)2 vitamin D level is the result of the ﬁne
regulation of production and degradation by cytochrome P450
enzymes. Genetic syndromes affecting production and degrad-
ation of 1,25 (OH)2 vitamin D have been described and further
subcategorized. Inactivating mutations in the CYP27B1 gene,
coding for 1-alpha hydroxylase, lead to vitamin D-resistant
rickets type 1a [47]. More debated is the role of CYP2R1 in
vitamin D-resistant rickets type 1b, as discussed previously.
Active 1,25(OH)2 vitamin D produces its effect by its interaction
with the VDR. Mutations in VDR provide severe peripheral re-
sistance to the effect of 1,25(OH)2 vitamin D and an autosomal
F IGURE 2 : Tissue expression of genes involved in the regulation of serum calcium concentration. (A) Genes present in parathyroid glands.
(B) Genes expressed in the bone. (C) Genes in the kidneys. PT, proximal tubule; TAL, thick ascending limb; CD, collecting duct.
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recessive disorder called vitamin D-resistant rickets type 2a char-
acterized by hypocalcaemia, hyperparathyroidism and rickets
[48]. The numerous VDR mutations described in this latter dis-
order have been reviewed recently by Malloy and Feldmann
[49]. Vitamin D-resistant rickets type 2b results from mutations
in a protein associated with the transduction complex.
Catabolism of 1,25(OH)2 vitamin D to biologically inactive
1,24,25(OH)3 vitamin D and calcitroic acid is achieved by the
P450 24-hydroxylase (CYP24A1), expressed in the proximal
and distal tubule of the kidney, as well as in the collecting duct
[50]. Human CYP24A1 mutations have been reported in idio-
pathic infantile hypercalcaemia [51]. If this rare condition is
due to clear loss of function mutations in the CYP24A1 gene,
more subtle genetic variant affecting only slightly the enzymat-
ic activity may lead to an increased sensitivity to vitamin D.
CONCLUSION
Calcium homeostasis in humans is regulated in part by genetic
factors, as illustrated by rare monogenic diseases. Serum calcium
levels are tightly regulated by two main hormonal systems,
i.e. PTH and vitamin D, which are themselves also inﬂuenced by
genetic factors. Recent technological advances in molecular
biology allow screening the human genome at an unprecedented
level of detail and using hypothesis-free approaches, such as
GWAS. GWAS identiﬁed novel loci for calcium-related pheno-
types that shed new light on the biology of calcium in humans
(Figure 2). There is likely a genetic and phenotypic continuum
between rare monogenic diseases of calcium homeostasis and
slight disturbances of calcium homeostasis in the general popu-
lation. Future studies using whole-exome and whole-genome se-
quencing will further advance our understanding of the genetic
architecture of calcium homeostasis in humans. These ﬁndings
will likely provide new insight into the complex mechanisms in-
volved in calcium homeostasis and hopefully lead to novel pre-
ventive and therapeutic approaches.
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